...
首页> 外文期刊>International Journal of Globalisation and Small Business >Towards definition of the global biotechnology value chain using cases from Australian biotechnology SMEs
【24h】

Towards definition of the global biotechnology value chain using cases from Australian biotechnology SMEs

机译:利用澳大利亚生物技术中小企业的案例来定义全球生物技术价值链

获取原文
获取原文并翻译 | 示例

摘要

The generic pharmaceutical value chain model has been employed to describe both the global pharmaceutical and biotechnology industries till now. This research investigates the organisational value chain in Australian biotechnology companies in order to assess the appropriateness of the pharmaceutical value chain to small-and medium-sized biotechnology companies. The main theme of the research is: Can a generic model of the organisational value chain be defined for the biotechnology industry? Emanating from the literature, two research propositions were developed: RP1: There are eight major definable elements/activities of the organisational value chain for the biotechnology industry. RP2: Coverage of the elements in the biotechnology value chain ranges from focussed to broad. A multiple case study methodology was used to explore these propositions. To develop a number of case studies data was collected from senior managers of small and medium Australian biotechnology companies using an interview instrument, as well as from publicly available documentation and through observation. The results were analysed using cross-case comparisons. The results showed that an aggregation of the value chains of each organisation can be reduced to these eight definable elements that constitute the biotechnology value chain: basic research, applied research, development, verification and validation, prototype development, clinical trials, manufacturing and marketing. However, the findings also indicate that these major elements of the value chain need to be further reduced into sub-activities or sub-tasks to cater for the unique differences between biotechnology companies. Generally, the findings were consistent with the literature. However, a wider sampling, including international biotechnology organisations should be studied. The major contribution of this research is in the development of a value chain model, including general sub-tasks, for the Australian biotechnology industry.
机译:到目前为止,通用制药价值链模型已被用于描述全球制药和生物技术行业。这项研究调查了澳大利亚生物技术公司的组织价值链,以评估医药价值链对中小型生物技术公司的适用性。研究的主题是:是否可以为生物技术行业定义组织价值链的通用模型?从文献中得出了两个研究命题:RP1:生物技术行业组织价值链的八个主要可定义要素/活动。 RP2:生物技术价值链中各个要素的覆盖范围从重点到广泛。多案例研究方法被用来探索这些命题。为了开发大量案例研究,使用访谈工具从澳大利亚中小型生物技术公司的高级管理人员那里收集了数据,并从公开的文档中并通过观察收集了这些数据。使用跨案例比较分析结果。结果表明,每个组织的价值链的聚集可以简化为构成生物技术价值链的这八个可定义要素:基础研究,应用研究,开发,验证和确认,原型开发,临床试验,制造和销售。但是,研究结果还表明,价值链的这些主要要素需要进一步简化为子活动或子任务,以适应生物技术公司之间的独特差异。通常,研究结果与文献一致。但是,应该研究更广泛的样本,包括国际生物技术组织。这项研究的主要贡献在于为澳大利亚生物技术产业开发了一个价值链模型,包括一般的子任务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号